Sexual Function & Performance
12/08/2026
Peptides and growth factors are biological signalling molecules that can influence cellular behaviour, tissue maintenance and repair. Research is investigating how specific molecules interact with pathways involved in cellular survival, proliferation, migration, angiogenesis, inflammation, extracellular-matrix remodelling and tissue regeneration.
Research into cellular repair and recovery explores pathways relevant to:
It is important to distinguish between different types of biological compounds. IGF-1 is a peptide growth factor and hormone, while thymosin β4 is a naturally occurring peptide. TB-500 is generally described as a synthetic peptide associated with a sequence derived from thymosin β4. BPC-157 is a synthetic experimental peptide, while GHK-Cu is a naturally occurring copper-binding peptide.
The strength and type of evidence therefore varies considerably between compounds.
Insulin-like growth factor-1 (IGF-1) is a peptide growth factor involved in cellular growth, proliferation, differentiation and survival. IGF-1 binds primarily to the IGF-1 receptor (IGF-1R), activating intracellular signalling pathways including PI3K/Akt and MAPK that can influence cell survival, proliferation and tissue responses.
Research has investigated IGF-1 in relation to wound healing, epithelial-cell migration, fibroblast activity, extracellular-matrix production and tissue regeneration. Experimental wound-healing research has reported effects on keratinocyte migration, re-epithelialisation, wound contraction and extracellular-matrix components such as hyaluronan.
Systematic research has also examined the role of IGF-1 in wound-healing processes, while highlighting that much of the available evidence remains experimental and that relatively few human clinical studies have directly evaluated IGF-1 as a therapeutic wound-healing intervention.
The research pathway can therefore be summarised as:
IGF-1 → IGF-1R signalling → PI3K/Akt & MAPK pathways → cellular survival/proliferation → migration & matrix activity → tissue repair
IGF-1 therefore represents an important growth-factor pathway within cellular-repair research, although its systemic biological effects mean that the distinction between physiological signalling and therapeutic administration is particularly important.
BPC-157 is a synthetic pentadecapeptide that has attracted considerable interest within experimental regenerative-medicine research. Studies have investigated its effects on angiogenesis, fibroblast activity, nitric-oxide signalling, collagen formation and tissue repair.
Preclinical research has reported effects involving VEGFR2 and nitric-oxide signalling, including activation of the Akt-eNOS pathway. These mechanisms have been investigated in experimental models involving muscle, tendon, ligament, vascular and gastrointestinal injury.
The broader research pathway can therefore be summarised as:
VEGFR2 / NO signalling → angiogenesis → fibroblast activity → extracellular-matrix formation → tissue repair
Despite the large amount of experimental research, the evidence remains predominantly preclinical. Recent reviews have highlighted the lack of sufficient high-quality human clinical evidence required to establish efficacy and safety in people [2].
BPC-157 should therefore be regarded as an experimental research compound, rather than an established cellular-repair treatment.
Thymosin β4 (Tβ4) is a naturally occurring 43-amino-acid peptide involved in several cellular processes, particularly actin regulation and cell migration.
Research has investigated Tβ4 in relation to keratinocyte migration, endothelial-cell migration, angiogenesis, wound closure, inflammation, collagen deposition and extracellular-matrix remodelling.
TB-500 is commonly described as a synthetic peptide associated with the LKKTETQ sequence within thymosin β4. This sequence is associated with the actin-binding activity of thymosin β4 and has generated interest in cellular migration and tissue-repair research.
The distinction between the two is important when interpreting the scientific literature. A substantial proportion of the peer-reviewed evidence concerns full-length thymosin β4 rather than TB-500 specifically. Findings from thymosin β4 studies should therefore not automatically be interpreted as direct clinical evidence for TB-500.
Research involving thymosin β4 has demonstrated effects across several wound-healing models, including effects on cell migration, angiogenesis, extracellular-matrix activity and tissue remodelling. Clinical research has also investigated thymosin β4 in conditions including difficult-to-heal wounds.
The broader research pathway can therefore be summarised as:
Thymosin β4 / TB-500-related actin signalling → cell migration → endothelial activity → angiogenesis → wound closure → tissue remodelling
Thymosin β4 is one of the more extensively researched peptides within tissue-repair biology. TB-500, however, has substantially less direct human clinical evidence, meaning that evidence for full-length thymosin β4 should not be presented as proof of clinical efficacy for TB-500.
GHK-Cu (glycyl-L-histidyl-L-lysine–copper) is a naturally occurring copper-binding peptide that has been studied extensively in connective-tissue biology.
Research has investigated its effects on fibroblast activity, collagen synthesis, growth-factor signalling and extracellular-matrix remodelling. Experimental research has demonstrated stimulation of collagen synthesis in fibroblast cultures, providing a biological basis for further investigation into its role in connective-tissue repair.
Research into GHK-Cu has also examined its relationship with matrix metalloproteinase activity and broader extracellular-matrix remodelling.
The cellular-repair pathway can therefore be summarised as:
Fibroblast signalling → collagen synthesis → extracellular-matrix activity → tissue remodelling → repair
GHK-Cu consequently represents an established area of experimental research within connective-tissue and skin biology.
| Peptide / growth factor | Biological pathway investigated | Primary research area |
|---|---|---|
| IGF-1 | IGF-1R, PI3K/Akt, MAPK, proliferation & survival | Cellular & tissue repair |
| BPC-157 | VEGFR2, Akt-eNOS, angiogenesis | Soft-tissue repair |
| Thymosin β4 / TB-500 | Actin regulation, cell migration & angiogenesis | Cellular & tissue repair |
| GHK-Cu | Fibroblast, collagen & ECM signalling | Connective-tissue repair |
Research into cellular repair involves several distinct biological strategies.
Growth-factor signalling, represented by IGF-1, can influence cellular proliferation, survival and migration.
Tissue-repair peptides, such as thymosin β4, have been investigated in relation to cell migration, angiogenesis, wound closure and extracellular-matrix remodelling.
Experimental peptides such as BPC-157 and TB-500 are being investigated for potential regenerative effects, but the level of direct human evidence is substantially lower than the amount of preclinical research surrounding them.
Connective-tissue peptides such as GHK-Cu have been investigated in relation to fibroblast activity, collagen synthesis and extracellular-matrix regulation.
These mechanisms should not be treated as interchangeable. Increased angiogenesis, fibroblast activity, cellular proliferation or collagen production does not automatically demonstrate improved functional recovery in humans.
The strength of evidence therefore depends on the compound and the specific outcome being studied. Laboratory and cellular models can identify mechanisms, while animal models provide information about tissue-level responses. Controlled human clinical studies are required to establish whether a particular intervention produces meaningful clinical benefit and has an acceptable safety profile.
For thymosin β4 and TB-500 specifically, the distinction between the two compounds should be maintained when interpreting evidence. Thymosin β4 has a substantially larger peer-reviewed research base, including human studies, whereas direct clinical evidence for TB-500 is much more limited.
1. Zhang, X. et al. (2021) ‘Insulin-like growth factor-1 and wound healing: a systematic review’, International Wound Journal.
2. McGuire, F.P., Martinez, R., Lenz, A., Skinner, L. and Cushman, D.M. (2025) ‘Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing’, Current Reviews in Musculoskeletal Medicine, 18(12), pp. 611–619. doi:10.1007/s12178-025-09990-7.
3. Kleinman, H.K. and Sosne, G. (2016) ‘Thymosin β4 promotes dermal healing’, Vitamins and Hormones, 102, pp. 251–275. doi:10.1016/bs.vh.2016.04.005.
4. Adnan, S.B., Maarof, M., Fauzi, M.B. and Fadilah, N.I.M. (2025) ‘Exploring the role of tripeptides in wound healing and skin regeneration: a comprehensive review’, International Journal of Medical Sciences, 22(16), pp. 4175–4200. doi:10.7150/ijms.118118.
The information presented on this page summarises published scientific research and is provided for educational purposes.
Evidence varies considerably between compounds and between biological outcomes. Laboratory, cell-culture and animal studies can provide evidence for mechanisms of action but do not establish that a compound is safe or effective as a treatment in humans.
In particular, the existence of research involving a biological pathway does not demonstrate that administration of the corresponding peptide or growth factor will produce the same effect clinically.
IGF-1, BPC-157, TB-500, thymosin β4 and GHK-Cu should therefore be considered according to their individual evidence base rather than being treated as equivalent regenerative agents.
Experimental peptides and growth factors should not be assumed to be safe or effective for personal use. The information above is not medical advice or a recommendation for treatment.
